


Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Sheet 1 of 4

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known	
Application Number	10/723,431
Filing Date	November 26, 2003
First Named Inventor	Hu, Ning
Group Art Unit	1615
Examiner Name	Unknown

Attorney Docket No: 1992.007US1

US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
<i>hu</i>	US-3,993,754	11/23/1976	Rahman, Yueh-Erh , et al.	10/09/1974
	US-4,145,410	03/20/1979	Sears, Barry D.	06/17/1997
	US-4,224,179	09/23/1980	Schneider, Michel	09/23/1980
	US-4,235,871	11/25/1980	Papahadjopoulos, Demetrios P., et al.	02/24/1978
	US-4,522,803	06/11/1985	Lenk, Robert P., et al.	03/24/1983
	US-4,588,578	05/13/1986	Fountain, Michael W., et al.	08/08/1983
	US-4,753,788	06/28/1988	Gamble, Ronald C.	01/31/1985
	US-4,885,172	12/05/1989	Bally, M. B., et al.	12/15/1986
	US-4,938,949	07/03/1990	Borch, Richard F., et al.	09/12/1988
	US-4,946,683	08/07/1990	Forssen, Eric A.	08/04/1989
	US-5,077,056	12/31/1991	Bally, M. B., et al.	12/12/1988
	US-5,316,771	05/31/1994	Barenholz, Yechezkel , et al.	12/18/1992
	US-5,380,531	01/10/1995	Chakrabarti, Ajoy , et al.	06/02/1992
	US-5,616,341	04/01/1997	Mayer, L. D., et al.	08/26/1993
	US-5,795,589	08/18/1998	Mayer, Lawrence D., et al.	02/05/1997
	US-5,814,335	09/29/1998	Webb, Murray S., et al.	09/17/1997
<i>hu</i>	US-6,083,530	07/04/2000	Mayer, Lawrence D., et al.	05/26/1998

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
<i>hu</i>	EP-0290296A2	11/09/1988	Bally, M. B., et al.	
	EP-0546951A1	06/16/1993	Ostro, Marc J.	
	EP-0719546A1	07/03/1996	Bally, Marcel B., et al.	
	WO-0105372A2	01/25/2001	Abra, R. M., et al.	
	WO-03041682A3	05/22/2003	Webb, Murray , et al.	
	WO-8601102A1	02/27/1986	Bally, Marcel B., et al.	
	WO-8700238	01/15/1987	Rudham, Robert C., et al.	
	WO-9202244A1	02/20/1992	Chakrabarti, A. , et al.	
<i>hu</i>	WO-9913816A2	03/25/1999	Moynihan, Karen L., et al.	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>hu</i>		"International Search Report, for Application No. PCT/US 03/37964, date mailed July 5, 2004", 11 Pages	
<i>hu</i>		ADLAKHA-HUTCHEON, G. , et al., "Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity", <u>Nature Biotechnology</u> , 17(8), (August 1999),775-779	

EXAMINER

Kuhn

DATE CONSIDERED

3/20/07

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>		Complete if Known Application Number 10/723,431 Filing Date November 26, 2003 First Named Inventor Hu, Ning Group Art Unit 1615 Examiner Name Unknown	
Sheet 2 of 4		Attorney Docket No: 1992.007US1	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. †	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
<i>hu</i>		BANDAK, S. , et al., "Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models", <u>Anticancer Drugs</u> , 10, (November 10, 1999),911-920	
		BANGHAM, A D., "Diffusion of univalent ions across the lamellae of swollen phospholipids", <u>Journal of Molecular Biology</u> , 13(1), (August 1965),238-52	
		COLBERN, C. T., et al., "Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model", <u>Journal of Inorganic Biochemistry</u> , 77(1-2), (October 1999),117-120	
		CRAMER, J. A., "NMR Studies of pH-Induced Transport of Carboxylic Acids Across Phospholipid Vesicle Membranes", <u>Biochemical and Biophysical Research Communications</u> , 75(2), (1977),295-301	
		DEAMER, DAVID W., et al., "Liposome Preparation: Methods and Mechanisms", Chapter 1 - In: <u>Liposomes by Marc Ostro</u> , New York : M. Dekker,(1983),27-51	
		DEAMER, D W., et al., "The response of fluorescent amines to pH gradients across liposome membranes", <u>Biochimica et Biophysica Acta</u> , 274(2), (August 9, 1972),323-35	
		DEMARIO, M. D., et al., "A Phase I Study of Liposome-Formulated Cisplatin (SPI-77 R) Given Every 3 Weeks in Patients With Advanced Cancer", <u>Proceedings of ASCO</u> , Vol. 17, http://www.asco.org/ac/1,1003,_12-002643-00_18-0031-00_19-006314,00.asp ,(1998),Abstract 883	
		FORSEN, E A., "Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes", <u>Cancer Research</u> , 43(2), (February 1983),546-50	
		GABIZON, A , "Enhancement of adriamycin delivery to liver metastatic cells with increased tumorcidal effect using liposomes as drug carriers", <u>Cancer Research</u> , 43(10), (October 1983),4730-5	
		GABIZON, A , "Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice", <u>Cancer Research</u> , 42(11), (November 1982),4734-9	
		GANAPATHI, R , "Effect of cholesterol content of liposomes on the encapsulation, efflux and toxicity of adriamycin", <u>Biochem Pharmacol.</u> , 33(4), (February 15, 1984),698-700	
<i>hu</i>		HARRINGTON, K. J., et al., "Phase II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer", <u>Annals of Oncology</u> , 12(4), (April 2001),493-496	
<i>hu</i>		HERMAN, E H., et al., "Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation", <u>Cancer Research</u> , 43(11), (November 1983),5427-32	

EXAMINER

Ku

DATE CONSIDERED 3/16/07

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/723,431
		Filing Date	November 26, 2003
		First Named Inventor	Hu, Ning
		Group Art Unit	1615
		Examiner Name	Unknown
Sheet 3 of 4		Attorney Docket No: 1992.007US1	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No [†]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
hu		HONG, R L., et al., "Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice is surface coating with polyethylene glycol beneficial?", <u>Clinical Cancer Research</u> , 5(11), (November 1999), 3645-3652	
		LIM, H. J., et al., "Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 281(1), (April 1997), 566-573	
		LOPEZ-BERESTEIN, G , et al., "Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study", <u>The Journal of Infectious Diseases</u> , 151(4), (April 1985), 704-10	
		MEERUM TERWOGT, J. M., et al., "Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin", <u>Cancer Chemotherapy and Pharmacology</u> , 49(3), (March 2002), 201-210	
		MINOW, ROBERT A., "Adriamycin (NSC-123127) Cardiomyopathy - An Overview with Determination of Risk Factors", <u>Cancer Chemother Reports</u> , Part 3, 6(2), (October 1975), 195-201	
		NEWMAN, M. S., et al., "Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice", <u>Cancer Chemotherapy and Pharmacology</u> , 43(1), Erratum in <u>Cancer Chemotherapy and Pharmacology</u> , 43(6), 524 (attached to downloaded document), (1999), 1-7	
		OLSON, F. "Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes", <u>European Journal of Cancer & Clinical Oncology</u> , 18(2), (February 1982), 167-76	
		PAPAHADJOPoulos, D, "Phospholipid model membranes. I. Structural characteristics of hydrated liquid crystals", <u>Biochimica et Biophysica Acta</u> , 135(4), (September 9, 1967), 624-638	
		RAHMAN, A , "Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration", <u>Cancer Research</u> , 42(5), (May 1982), 1817-25	
		RAHMAN, A , "Liposomal protection of adriamycin-induced cardiotoxicity in mice", <u>Cancer Research</u> , 40(5), (May 1980), 1532-7	
		RAHMAN, A , "Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes", <u>Cancer Research</u> , 45(2), (February 1985), 796-803	
		RICHARDSON, V , "Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients", <u>British Journal of Cancer</u> , 40(1), (July 1979), 35-43	
hu		ROSA, P , "Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration", <u>Pharmacology</u> , 26(4), (1983), 221-9	

EXAMINER

ku

DATE CONSIDERED

3/26/07

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/723,431
		Filing Date	November 26, 2003
		First Named Inventor	Hu, Ning
		Group Art Unit	1615
		Examiner Name	Unknown
Sheet 4 of 4		Attorney Docket No: 1992.007US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
hu		ROSA, P., et al., "Liposomes containing Doxorubicin - an example of drug targeting", In: <u>Transport in biomembranes : model systems and reconstitution</u> edited by Rezo Antolini, New York : Raven Press, (1982), 243-256	
hu		RYMAN, BRENDA E., et al., "Liposomes: Further Considerations of their possible role as carriers of therapeutic agents", In: <u>Targeting of drugs</u> edited by Gregory Gregoriadis, New York : Plenum Press, (1982), 235-248	
		SZOKA, F., "Comparative properties and methods of preparation of lipid vesicles (liposomes).", <u>Annual Review of Biophysics and Bioengineering</u> , 9, (1980), 467-508	
		VEAL, G. J., et al., "A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin", <u>British Journal of Cancer</u> , 84(8), (April 2001), 1029-1035	
hu		WORKING, P. K., et al., "Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys", <u>Toxicological Sciences</u> , 46(1), (November 1998), 155-165	

EXAMINER

lcn

DATE CONSIDERED

3/20/07